Stony Brook University

About: Stony Brook University is a education organization based out in Stony Brook, New York, United States. It is known for research contribution in the topics: Population & Poison control. The organization has 32534 authors who have published 68218 publications receiving 3035131 citations. The organization is also known as: State University of New York at Stony Brook & SUNY Stony Brook.

NMR studies of cathode materials for lithium-ion rechargeable batteries.

Abstract: Lithium intercalation or insertion materials have been widely investigated in the search for new electrode materials for use in high-voltage rechargeable batteries.1-6 The first commercial Li-ion rechargeable battery contains the layered materials LiCoO2 (Figure 1) and graphite as the cathode (or positive electrode) and anode (or negative electrode), respectively.7 Although this battery is the current standard in many applications including cell phones and laptops, its slow charge and discharge rates and cost have prevented its use in applications that require cheap high power and capacity, such as hybrid electric vehicles and electric vehicles. The toxicity of Co is also an issue. A wide variety of materials have been studied,5,6 which include doped LiCoO2 phases, layered compounds based on the LiCoO2 structure (e.g., LiNiO2 8 and LiNi0.5Mn0.5O2 9,10),

The Revised Fibromyalgia Impact Questionnaire (FIQR): Validation and psychometric properties

Abstract: Introduction The Fibromyalgia Impact Questionnaire (FIQ) is a commonly used instrument in the evaluation of fibromyalgia (FM) patients. Over the last 18 years, since the publication of the original FIQ, several deficiencies have become apparent and the cumbersome scoring algorithm has been a barrier to widespread clinical use. The aim of this paper is to describe and validate a revised version of the FIQ: the FIQR.

Genetics of poliovirus.

Abstract: INFECTIOUS eDNA AND IN VITRO SYNTHESIS OF INFECTIOUS VIRAL RNA 359 SELECTION AND GENERATION OF MUTANTS . . . . . . .... . . .. . . .. . . 360 Selection of Spontaneous Mutants . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 363 Random Mutagenesis .... _ . . . . . . . _ _ .... ... ... _ _ . . . . . . . . . 370 Mutagenesis Targeted to Existing or de novo Introduced Restriction Sites . . . . 370 Oligonucleotide-mediated, Site Directed Mutagenesis. . . . . . . . . . . . . . . . . . 371 Exchange of Genomic Segments . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 371 In Search for Revertants . . . . .. . .. . . .. . . . . . . .. . . . . . .. ..... . . 372

PhosphoSite: A bioinformatics resource dedicated to physiological protein phosphorylation.

Abstract: PhosphoSite is a curated, web-based bioinformatics resource dedicated to physiologic sites of protein phosphorylation in human and mouse. PhosphoSite is populated with information derived from published literature as well as high-throughput discovery programs. PhosphoSite provides information about the phosphorylated residue and its surrounding sequence, orthologous sites in other species, location of the site within known domains and motifs, and relevant literature references. Links are also provided to a number of external resources for protein sequences, structure, post-translational modifications and signaling pathways, as well as sources of phospho-specific antibodies and probes. As the amount of information in the underlying knowledgebase expands, users will be able to systematically search for the kinases, phosphatases, ligands, treatments, and receptors that have been shown to regulate the phosphorylation status of the sites, and pathways in which the phosphorylation sites function. As it develops into a comprehensive resource of known in vivo phosphorylation sites, we expect that PhosphoSite will be a valuable tool for researchers seeking to understand the role of intracellular signaling pathways in a wide variety of biological processes.

Provocative tests with psychostimulant drugs in schizophrenia.

Abstract: The psychotogenic effects of psychostimulant drugs have provided a major line of evidence in support of the DA hypothesis of schizophrenia. To evaluate the effects of psychostimulant (PS) drug in schizophrenia and the clinical variables which may influence their expression, we reviewed 36 studies of PS drugs in patients with schizophrenia. Approximately 40% evidence a psychotogenic response to PS administration in doses that are subpsychotogenic in normals. Specific clinical variables appear to modify this response, including diagnosis, degree and type of psychopathology, stage of illness and pharmacologic status at the time of testing. Non-amphetamine-like PS drugs, e.g., methylphenidate, appear to have greater psychotogenic potency than amphetamine-like PS drugs. These results suggest the presence of a subgroup of schizophrenic patients who exhibit psychotic symptom activation with PS in a state dependent or independent fashion. This biologic phenomenon may be clinically exploitable and should be investigated further.